RNF125 expression is significantly downregulated in several cancers, including CCA, HCC and CRC, and is negatively correlated with the clinical stage, whereas higher expression is associated with better clinical outcomes [38,39,42]. This evidence concerns the gene RNF125 and hepatocellular carcinoma.